The biosimilar workshop hosted by the US Food and Drug Administration and the Federal Trade Commission was a sold-out event, drawing a swarm of participants who spilled into an overflow room. While it generated red hot interest among stakeholders, the meeting mostly provided a snapshot of the current biosimilar market with oft-stated recommendations of what could be done to tear down barriers to biosimilar use.
But the 9 March workshop was still a landmark event, illustrating the commitment by FDA and the FTC to take action against behavior impeding the uptake of biosimilars and to promote competition in the biologics markets – and in some ways a reminder of the interchange of ideas
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?